Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.0 million.

  • Rocket Pharmaceuticals' Income from Continuing Operations rose 2414.68% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 745.13%. This contributed to the annual value of -$266.8 million for FY2024, which is 412.81% down from last year.
  • Rocket Pharmaceuticals' Income from Continuing Operations amounted to -$52.0 million in Q3 2025, which was up 2414.68% from -$71.1 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Income from Continuing Operations peaked at -$33.8 million during Q2 2021, and registered a low of -$71.9 million during Q2 2024.
  • For the 5-year period, Rocket Pharmaceuticals' Income from Continuing Operations averaged around -$57.9 million, with its median value being -$61.6 million (2024).
  • The largest annual percentage gain for Rocket Pharmaceuticals' Income from Continuing Operations in the last 5 years was 2753.09% (2021), contrasted with its biggest fall of 7122.35% (2021).
  • Rocket Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$43.9 million in 2021, then plummeted by 55.43% to -$68.3 million in 2022, then rose by 7.86% to -$62.9 million in 2023, then rose by 2.2% to -$61.6 million in 2024, then grew by 15.5% to -$52.0 million in 2025.
  • Its Income from Continuing Operations stands at -$52.0 million for Q3 2025, versus -$71.1 million for Q2 2025 and -$63.5 million for Q1 2025.